

RITA MEDICAL SYSTEMS INC  
Form 8-K  
June 09, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**June 8, 2004**

Date of Report

(Date of earliest event reported)

**RITA Medical Systems, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-30959**

(Commission File Number)

**94-3199149**

(I.R.S. Employer Identification No.)

**967 N. Shoreline Blvd.**

**Mountain View, CA 94043**

(Address of principal executive offices, with zip code)

**(650) 314-3400**

(Registrant's telephone number, including area code)

**Item 5. Other Events and Required FD Disclosure.**

On June 8, 2004, RITA Medical Systems, Inc., a Delaware corporation, announced that early results from an international multicenter prospective clinical trial show a 92% survival rate in stage 1 non-small cell lung cancer patients treated with radiofrequency ablation as the sole anti-cancer treatment. A copy of the release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RITA Medical Systems, Inc.**

Date: June 9 2004

By: /s/ Donald Stewart

---

Donald Stewart, Chief Financial Officer and  
Vice President Finance and Administration

---

**RITA MEDICAL SYSTEMS, INC.**

**INDEX TO EXHIBITS**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release of RITA Medical Systems, Inc. dated June 8, 2004.